These results are in contrast to what was reported with baricitinib in the RA-BEAM trial, in which baricitinib showed superiority over adalimumab in the ACR20 response rate and mean change in DAS28-CRP at week 12 [119]. This evidence concerns the gene CRP and rheumatoid arthritis.